May 12-13, 2026 – New Brunswick, NJ
Meet Veristat at the ASGCT Annual Meeting
April 30, 2026
May 11-15, 2026 – Boston, MA
🔬 Where Cell and Gene Therapy Moves Forward
Veristat is pleased to attend the ASGCT Annual Meeting, where leaders across cell and gene therapy come together to share progress, tackle challenges, and shape what comes next. As programs advance through early-phase development, the stakes are high. Scientific complexity, evolving regulatory expectations, and the need for clear, defensible data all converge at this stage.
Our team looks forward to connecting with sponsors and innovators to discuss how Veristat supports cell and gene therapy programs with integrated regulatory, clinical, and biostatistical expertise. The focus is simple: make development capital count and enable faster, more confident decisions as therapies move closer to patients.
Connect with Veristat at Precision Clinical Trials in Boston
April 24, 2026
April 30, 2026 | Boston
⚛️ Where Clinical Strategy Meets Execution That Holds Up Under Scrutiny
On April 30, we will be attending the Precision Clinical Trials Summit Boston, where clinical development and operations leaders come together to address the complexities shaping modern trials. As study designs evolve and expectations for speed and precision increase, success depends on more than execution. It requires clear strategy, disciplined planning, and data that supports confident decisions at every stage.
Our team looks forward to meeting with biotech and clinical leaders to discuss how Veristat helps sponsors reduce rework, improve decision speed, and make every dollar of development capital count.
Meet Veristat at Swiss Biotech Day 2026
April 24, 2026
May 3–5, 2026 – Basel, Switzerland
⚛️ Where Global Biotech Comes Together
Veristat is pleased to attend Swiss Biotech Day 2026, one of Europe’s leading biotechnology conferences, bringing together innovators, investors, and development leaders at the heart of Switzerland’s life sciences ecosystem.
As partnerships form and programs take shape, early alignment and clear development strategy play a critical role in setting therapies up for success. And as sponsors advance through early and mid-stage development, the margin for error narrows. Progress depends on disciplined clinical planning, strong statistical foundations, and regulatory clarity that holds up under scrutiny.
Our team looks forward to connecting with biotech leaders to discuss how Veristat helps move complex programs forward while making every dollar of development capital count.